Fate Therapeutics (FATE) Jefferies Global Healthcare Conference summary
Event summary combining transcript, slides, and related documents.
Jefferies Global Healthcare Conference summary
18 Nov, 2026CAR T platform and access
CAR T-cells were presented as living drugs that expand in response to disease burden, unlike conventional medicines whose effects can decline over time.
The off-the-shelf platform is designed for safety, scalable manufacturing, broad access and outpatient delivery, with a goal of extending CAR T use into rheumatology and other inflammatory or fibrotic diseases.
iPSC clone selection creates a uniform starting cell for manufacturing; the master cell bank approach is intended to support consistent, high-volume inventory.
A CAR T-cell dose was estimated at $3,000 at current inventory and volume levels, with cost expected to decline as production scales; current working volume is in the hundreds of liters.
FT819 in autoimmune disease
More than 35 patients had been treated; grade 1–2 CRS occurred in ~17%, while infection and cytopenia rates were described as very low with less intensive conditioning.
Clinical data showed rapid reductions in lupus disease activity and UPCR; standard-of-care medications were discontinued from day -5 before FT819 administration.
A potentially registrational lupus nephritis trial had started under FDA RMAT designation and CDRP inclusion: single-arm, 53 patients, one FT819 dose, and complete renal response at six months as the primary endpoint.
Three extrarenal lupus patients responded without conditioning chemotherapy; two achieved DORIS and one LLDAS. In a separate multi-dose case, SLEDAI fell from 10 to 2 within one month and LLDAS was reached by month two.
In systemic sclerosis, all patients achieved rCRISS of 25 or better, with skin scores improving; further trial updates were anticipated.
FT839 and broader autoimmune development
FT839 is designed to target activated, aberrant immune cells across cell types while sparing resting immune cells; its engineering targets CD19 and CD38.
The COMPLETE trial was recruiting and activating sites, with no conditioning chemotherapy planned; an update was expected early in 2027.
Latest events from Fate Therapeutics
- $100 million Leerink ATM adds financing flexibility but carries material dilution risk.FATE
Registration filing - RECLAIM-LN advanced as management’s grant-inclusive runway outlook extended to mid-2028.FATE
Q3 2026 - Scalable CAR T platform shows strong safety, efficacy, and promising phase II progress in lupus nephritis.FATE
12th Annual Cantor Fitzgerald Global Healthcare Conference - Net loss narrowed, cash runway into 2028, and pivotal CAR T-cell trials advanced.FATE
Q2 2026 - Early lupus trial data with flexible CAR T protocols expected by year-end, focusing on B-cell reset.FATE
Jefferies 2024 Global Healthcare Conference - FT819 and next-gen CAR T-cell therapies show strong clinical progress and financial stability.FATE
Corporate presentation - Net loss narrowed on lower expenses, with strong cash and key CAR T-cell advances, but risks remain.FATE
Q1 2026 - Key votes include director elections, auditor ratification, and incentive plan amendment.FATE
Proxy filing - Shareholders will vote on director elections, auditor ratification, say-on-pay, and equity plan expansion.FATE
Proxy filing